Does atenolol cause more weight gain than metoprolol?

Mixed data, with a slight edge toward atenolol causing more. Meta-analyses tend to show atenolol users gaining modestly more, typically 0.5 to 1.5 kg more over 12 months, than metoprolol users at equivalent antihypertensive doses. The effect is small enough that switching between the two for weight reasons alone is rarely the right move.

Which beta blocker causes the least weight gain?

Carvedilol and nebivolol. Both are vasodilating beta blockers: carvedilol through alpha-1 blockade, nebivolol through nitric oxide release. Head-to-head studies consistently show carvedilol and nebivolol users gaining less weight than metoprolol, atenolol, and propranolol users, with nebivolol often the most weight-neutral of the commonly prescribed options.

Is propranolol worse for weight than atenolol or metoprolol?

Roughly comparable. Propranolol is a non-selective, non-vasodilating beta blocker with a similar metabolic profile to atenolol and metoprolol. The underlying mechanisms that drive weight gain, reduced resting metabolic rate, capped exercise capacity, and decreased NEAT, apply here too.

Can I switch beta blockers to lose weight?

Only if your indication allows it, and only with your cardiologist's approval. For essential hypertension or migraine prevention, switching to carvedilol or nebivolol is often clinically reasonable and may improve weight trajectory. For heart failure with reduced ejection fraction, post-MI, or specific arrhythmias, the guideline-directed agents are narrower and switching for weight reasons may not be appropriate.

Does the dose matter for beta-blocker weight gain?

Yes. Weight gain with beta blockers is roughly dose-dependent within each agent. A man on metoprolol 25 mg twice daily typically gains less than a man on 100 mg twice daily, all else equal. If you are on a beta blocker for blood pressure control that is now stable, your cardiologist may be able to reduce the dose, which usually reduces the weight effect proportionally.

Will GLP-1 work on any beta blocker?

Yes. GLP-1 receptor agonists work through gut-brain satiety pathways, slowed gastric emptying, and insulin regulation, none of which overlap with beta-blocker mechanisms. Whether you are on atenolol, metoprolol, propranolol, carvedilol, or nebivolol, GLP-1 produces weight loss through its own independent mechanism.

testosterone24

Atenolol vs Metoprolol Weight Gain: Which Beta Blocker Is Worse for Your Waist

Back to Articles

Guide 9 min read Apr 24, 2026

Atenolol vs Metoprolol Weight Gain: Which Beta Blocker Is Worse for Your Waist

Mechanism by mechanism: which beta blocker is harder on your waist, and what you can actually do about it

If you are asking this question, you probably already know the bigger answer: both of them drive weight gain, neither is happy news, and your cardiologist is going to tell you that is a known side effect and move on. Here is the actual comparison, mechanism by mechanism, plus where propranolol fits, why carvedilol and nebivolol are the weight-neutral outliers, and when switching agents is a legitimate conversation.

The Short Answer

In meta-analyses and head-to-head trials, atenolol users tend to gain modestly more weight than metoprolol users, roughly 0.5 to 1.5 kg more over 12 months at equivalent antihypertensive doses. The difference is real but small. Within either drug, the dose matters more than the choice between them. Both are cardioselective beta-1 blockers without vasodilating activity, which puts them in the same pharmacologic class from a metabolic standpoint. Carvedilol and nebivolol, because they cause vasodilation through different mechanisms, partially offset the metabolic drop that drives weight gain in atenolol and metoprolol. So: if you are choosing between atenolol and metoprolol and weight is your concern, metoprolol has a slight edge. If you are choosing between either of them and a vasodilating agent and your indication allows it, carvedilol or nebivolol is meaningfully better on weight.

0.5-1.5 kg

More gain on atenolol vs metoprolol

Over 12 months in meta-analyses

2.0-2.5 kg

Atenolol annual weight gain

At moderate doses in hypertension trials

1.5-2.5 kg

Metoprolol annual weight gain

At moderate doses

Weight neutral

Carvedilol and nebivolol

Vasodilating beta blockers

The Five Beta Blockers Compared

Atenolol is a cardioselective beta-1 blocker without vasodilating activity, typically dosed 25 to 100 mg daily, used for hypertension, angina, post-MI, and arrhythmias. It is renally cleared and has been associated with somewhat higher rates of weight gain in meta-analyses than metoprolol, though study heterogeneity makes precise comparison difficult. Metoprolol comes in two formulations: tartrate (immediate release, typically twice daily) and succinate (extended release, once daily). Typical dose range is 25 to 200 mg daily total. Tartrate shows somewhat more weight effect than succinate in some analyses, likely due to peak-trough dynamics. Propranolol is non-selective, blocking both beta-1 and beta-2 receptors, with a similar metabolic profile to atenolol and metoprolol. Because it is non-selective, it can also affect bronchial smooth muscle and mask hypoglycemia symptoms more completely in diabetic patients. Carvedilol adds alpha-1 blockade to its beta blockade, producing vasodilation that partially offsets the metabolic drop. The GEMINI trial showed meaningful metabolic advantages for carvedilol over metoprolol in diabetic hypertensive patients. Nebivolol is highly beta-1 selective with nitric oxide-mediated vasodilation and is among the most weight-neutral beta blockers studied.

Average Annual Weight Gain by Beta Blocker

Why the Vasodilating Agents Are Different

The weight gain from metoprolol, atenolol, and propranolol is driven largely by reduced peripheral blood flow and reduced thermogenesis. Blocking beta-1 receptors in adipose tissue and skeletal muscle lowers the baseline metabolic rate of those tissues. Vasodilating beta blockers counteract part of this through their non-beta mechanisms. Carvedilol's alpha-1 blockade dilates blood vessels, improving peripheral flow and partially preserving thermogenesis. Nebivolol's nitric oxide release does the same through a different pathway. The net effect is that carvedilol and nebivolol users see less of the resting metabolic rate drop that drives weight accumulation. It is not that these drugs do not block beta receptors. They do. It is that they add a second action that offsets part of the metabolic consequence.

What the Head-to-Head Data Shows

The GEMINI trial (2004) compared carvedilol versus metoprolol in 1,235 hypertensive diabetic patients. Weight gain was significantly lower on carvedilol, 0.17 kg versus 1.2 kg at 5 months, with better A1C trajectory on carvedilol. This trial is old but remains one of the cleanest head-to-heads. Pooled meta-analyses of beta-blocker trials show all agents produce weight gain, with atenolol and metoprolol slightly above average and nebivolol and carvedilol below. Real-world registry data is broadly consistent: non-vasodilating agents gain 1 to 3 kg more than vasodilating ones over 12 months at comparable indication-matched doses. The interpretation is that the class of beta blocker, vasodilating versus non-vasodilating, matters meaningfully more than the specific agent within a class.

Weight Gain Over 12 Months by Beta Blocker Class

Atenolol
Metoprolol succinate
Carvedilol
Nebivolol

When Switching Is Reasonable

For essential hypertension without heart failure with reduced ejection fraction, arrhythmia, or MI history, switching to carvedilol or nebivolol is often clinically flexible and may improve weight trajectory. For migraine prevention on propranolol, switching to topiramate or a CGRP inhibitor is sometimes possible depending on migraine pattern. For performance anxiety on propranolol, as-needed dosing may be sufficient without full suppression. Switching is not reasonable without specialist input for heart failure with reduced ejection fraction, where guideline-directed agents are specific (metoprolol succinate, carvedilol, bisoprolol), post-MI where the evidence-based agent set is narrow, or specific arrhythmias where rate control parameters may be tuned to a specific drug. Stopping cold is never appropriate: rebound hypertension and tachycardia are real risks in patients with cardiovascular disease. If you are on metoprolol or atenolol for essential hypertension and weight is a real concern, bring your weight trajectory data to your next cardiology appointment and ask directly whether a vasodilating beta blocker is clinically appropriate for your indication.

Where GLP-1 Fits

GLP-1 receptor agonists work independently of beta-blocker choice. The mechanism is gut-brain satiety signaling, slowed gastric emptying, and insulin regulation, none of which overlaps with beta-adrenergic pathways. Whether you are on atenolol, metoprolol, propranolol, carvedilol, or nebivolol, the GLP-1 weight-loss effect is broadly similar. The clinical considerations are also similar across beta blockers. GLP-1 modestly raises resting heart rate while beta blockers suppress it, so the net effect is still lower heart rate than off the beta blocker. GLP-1 lowers blood pressure slightly, and combined with weight loss and the beta blocker, the trend is favorable and may eventually allow dose reduction. For men on insulin or sulfonylureas, beta blockers can mask early hypoglycemia symptoms such as tremor and tachycardia while sweating usually remains as a warning. Men eligible for GLP-1, BMI 30 or above, or 27 or above with a comorbidity such as hypertension, can start GLP-1 regardless of which beta blocker they are on, with cardiology coordination.

Why Beta Blockers Cause Weight Gain

Reduced resting metabolic rate
Capped exercise capacity
Reduced NEAT
Insulin resistance increase

Key Takeaway

Atenolol and metoprolol are similar. Atenolol is slightly worse on weight in the aggregate data, but not enough to switch solely for that reason. Propranolol is comparable to both. Carvedilol and nebivolol are meaningfully better on weight because their vasodilating activity offsets part of the mechanism that drives the gain. The class of beta blocker, vasodilating versus non-vasodilating, matters more than the specific agent within a class.

Medical Disclaimer

GLP-1 receptor agonists are not approved to counteract beta-blocker weight gain. Beta-blocker changes are made by your prescribing cardiologist based on your specific indication. This article describes comparative data and individual decisions require clinician input.